Your browser doesn't support javascript.
loading
Evaluation of hepcidin-25/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte/reticulocyte parameters in hemodialysis patients.
Bakr, Salwa; Salem, Karem Mohamed; Rashed, Ahmed Mohammed; Tantawy, Mohamed E A; Elsary, Asmaa Younis; Shamardl, Hanan Abdelmoneam; Ezzat, Eman Mahmoud.
Afiliación
  • Bakr S; Clinical Pathology/ Hematology, Faculty of Medicine, Fayoum University, Fayoum, Egypt. Electronic address: Sbm00@fayoum.edu.eg.
  • Salem KM; Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
  • Rashed AM; Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
  • Tantawy MEA; Faculty of Medicine, Menoufia University, Egypt.
  • Elsary AY; Public Health and Community Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
  • Shamardl HA; Medical Pharmacology, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
  • Ezzat EM; Internal Medicine, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Hematol Transfus Cell Ther ; 2024 Aug 21.
Article en En | MEDLINE | ID: mdl-39179496
ABSTRACT

BACKGROUND:

Anemia-associated chronic kidney disease increases in more advanced stages with a subsequent acceleration in renal impairment progressing to end-stage renal disease. Although hepcidin and erythroferrone have been described as novel biomarkers of iron metabolism, there is still an area of ambiguity regarding iron utility in anemia-associated end-stage renal disease.

OBJECTIVES:

This study aims to determine the correlations between erythropoietin, erythroferrone, and hepcidin-25 in hemodialysis, and to evaluate the clinical utility of the hepcidin-25/erythroferrone ratio as a biomarker of erythropoiesis-stimulating agent effectiveness compared to reticulocyte maturation parameters.

METHODS:

Serum erythropoietin, erythroferrone, and hepcidin-25 levels in 35 dialysis-dependent patients on a maintenance dose of a short-acting erythropoiesis-stimulating agent were consequently assessed on Days 0, 5, and 7. The erythropoiesis activity was monitored by measuring the increment in reticulocyte maturation parameters.

RESULTS:

Though the effectiveness of erythropoiesis in these patients was not associated with the hepcidin-25/erythroferrone ratio, it was lower among those with effective erythropoiesis than those with ineffective erythropoiesis. The effective group showed a statistically significant increase in reticulocyte maturation parameters compared to the ineffective group.

CONCLUSIONS:

The findings show the pathogenesis of iron homeostasis in hemodialysis, the validity of hepcidin-25/erythroferrone ratio as a biomarker of erythropoiesis-stimulating agent effectiveness, and the advantageous monitoring of reticulocyte maturation measures to improve management of anemia-associated chronic kidney disease.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hematol Transfus Cell Ther Año: 2024 Tipo del documento: Article Pais de publicación: Brasil
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Hematol Transfus Cell Ther Año: 2024 Tipo del documento: Article Pais de publicación: Brasil